4-[4-[(4-甲脒基苯基)氨基]丁基氨基]苯甲脒 | 125880-82-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 4-[4-[(4-甲脒基苯基)氨基]丁基氨基]苯甲脒
• 中文别名: 1-O-己基-2,3,5-三甲基氢醌
• 英文名称: 1,4-bis(4-amidinoanilino)butane
• 英文别名: 4-[4-(4-Carbamimidoylanilino)butylamino]benzenecarboximidamide
• CAS: 125880-82-2
• 化学式: C₁₈H₂₄N₆
• 分子量: 324.429
• InChiKey: XPYWKLXCKKLGSB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  124
• 氢给体数：
  6
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1,4-bis(4-cyanoanilino)butane 以 乙醇 为溶剂， 生成 4-[4-[(4-甲脒基苯基)氨基]丁基氨基]苯甲脒
  参考文献：
  名称：

  Amidine derivatives for treating amyloidosis

  摘要：

  本发明涉及在治疗与淀粉样蛋白相关的疾病中使用脲类化合物。特别地，本发明涉及一种治疗或预防受试者淀粉样蛋白相关疾病的方法，包括向受试者施用治疗量的脲类化合物。本发明中可用的化合物包括以下公式的化合物，当施用时，可减少或抑制淀粉样蛋白纤维形成、神经退行性或细胞毒性：1

  公开号：

  US20040006092A1

文献信息

• Amidine derivatives for treating amyloidosis
  申请人：Neurochem, Inc.

  公开号：US20040006092A1

  公开（公告）日：2004-01-08

  The present invention relates to the use of amidine compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. Among the compounds for use according to the invention are those according to the following Formula, such that, when administered, amyloid fibril formation, neurodegeneration, or cellular toxicity is reduced or inhibited: 1

  本发明涉及在治疗与淀粉样蛋白相关的疾病中使用脲类化合物。特别地，本发明涉及一种治疗或预防受试者淀粉样蛋白相关疾病的方法，包括向受试者施用治疗量的脲类化合物。本发明中可用的化合物包括以下公式的化合物，当施用时，可减少或抑制淀粉样蛋白纤维形成、神经退行性或细胞毒性：1
• AMIDINE DERIVATIVES FOR TREATING AMYLOIDOSIS
  申请人：Neurochem (International) Limited

  公开号：EP1420773A1

  公开（公告）日：2004-05-26
• [EN] AMIDINE DERIVATIVES FOR TREATING AMYLOIDOSIS<br/>[FR] DERIVES D'AMIDINE DESTINES AU TRAITEMENT DE L'AMYLOSE
  申请人：NEUROCHEM INC

  公开号：WO2003017994A1

  公开（公告）日：2003-03-06

  The present invention relates to the use of amidine compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. Among the compounds for use according to the invention are those according to the following Formula (X), such that, when administered, amyloid fibril formation, neurodegeneration, or cellular toxicity is reduced or inhibited.
• [EN] AMIDINE DERIVATIVES FOR TREATING AMYLOIDOSIS<br/>[FR] DERIVES D'AMIDINE POUR LE TRAITEMENT DES AMYLOSES
  申请人：UNIV NORTH CAROLINA

  公开号：WO2003103598A2

  公开（公告）日：2003-12-18

  The present invention relates to the use of amidine compounds in the treatment of amyloid related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. Among the compounds for use according to the invention are those according to the following Formulae, such that, when administered, amyloid fibril formation, neurodegeneration, or cellular toxicity is reduced or inhibited. Formula I, Formula II, Formula III.
• Analogs of 1,5-bis(4-amidinophenoxy)pentane (pentamidine) in the treatment of experimental Pneumocystis carinii pneumonia
  作者：Richard R. Tidwell、Susan Kilgore Jones、J. Dieter Geratz、Kwasi A. Ohemeng、Michael Cory、James Edwin Hall

  DOI：10.1021/jm00166a026

  日期：1990.4

  A series of 33 analogues of the anti-Pneumocystis carinii drug 1,5-bis(4-amidinophenoxy)pentane (pentamidine) was synthesized for screening against a rat model of P. carinii pneumonia (PCP). Twenty-five of the compounds showed efficacy against PCP when compared to a saline-treated control group. Two compounds, 1,4-bis(4-amidinophenoxy)butane (butamidine, 6) and 1,3-bis(4-amidino-2-methoxyphenoxy)propane (DAMP, 16), were statistically more effective than the parent drug in treating PCP in the rat model of infection. In addition to their activity against PCP, the compounds were also evaluated for antitrypsin activity, ability to inhibit thymidylate synthetase, affinity for DNA, and toxicity. No correlation was observed between the tested molecular interactions of the diamidines and their effectiveness against PCP.